BioCentury
ARTICLE | Clinical News

BioChaperone Lispro: Phase Ib data

April 11, 2016 7:00 AM UTC

Top-line data from a double-blind, crossover, German Phase Ib trial in 36 Type I diabetics showed that subcutaneous BioChaperone Lispro U100 given at mealtime significantly reduced blood glucose excur...